Gaurav Shah, M.D., is the CEO of Rocket Pharmaceuticals since its merger in 2018. He has a strong background in pharmaceuticals, holding both an M.D. and an MBA. Before joining Rocket, he worked in various leadership roles at Novartis, overseeing...

Gaurav Shah, M.D., is the CEO of Rocket Pharmaceuticals since its merger in 2018. He has a strong background in pharmaceuticals, holding both an M.D. and an MBA. Before joining Rocket, he worked in various leadership roles at Novartis, overseeing major drug programs and clinical developments. Under his leadership, Rocket Pharmaceuticals has focused on innovative therapies, particularly in gene therapy, aiming to revolutionize how diseases are treated. In 2023, he received a total compensation of about $8 million, showcasing the responsibilities he carries. His previous experience at Eli Lilly included overseeing critical projects which led to successful drug approvals. Gaurav is known for driving corporate objectives related to clinical development and ensuring Rocket maintains a solid reputation in the industry. His journey reflects a blend of medical expertise and business acumen, aiming for groundbreaking advancements in healthcare.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

R

Gaurav Shah

CEO of Rocket Pharmaceuticals

Education

M.D. from Columbia University

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1975 - 50 years ago

CEO of Rocket Pharmaceuticals for

7 years 3 months (Jan 2018 - Present)

Previous Experience

Global Program Head for CART-19 at Novartis

Rivals

Competitors/colleagues of Gaurav Shah

Holdings

See how much did Gaurav Shah make over time.

Gaurav Shah holds a significant amount of Rocket Pharmaceuticals stock, showcasing his commitment to the company. In 2022, his holdings included over 2 million shares, valued at about $42 million. This is no small investment, indicating he has a lot...

Gaurav Shah holds a significant amount of Rocket Pharmaceuticals stock, showcasing his commitment to the company. In 2022, his holdings included over 2 million shares, valued at about $42 million. This is no small investment, indicating he has a lot at stake in the company's performance. His stock grants and options have fluctuated significantly over the years, with options set to be exercised over the next few years. As of the end of 2022, Shah's holdings represented a considerable portion of his wealth, emphasizing the alignment of his interests with those of the shareholders. It’s clear that as Rocket aims for success and growth, Shah's financial stakes rise and fall accordingly, demonstrating a direct correlation between company performance and his own financial outcomes.

Total Stock Sold

$2.99M

RCKT

$2.99M

157,877 RCKT shares

What if they kept their stock?

If Gaurav Shah didn't sell their stock, today they would have:
Extra RCKT157,877 shares worth $2.45M.
This is -17.97% and $537.41K less than what they got when they sold the stock.

Charitable Transactions

RCKT

406,238 shares

RCKT

Recent Charitable Transactions

RCKT

406,238 shares

RCKT

Dec 31, 2020

Charity

Insider Trading

See recent insider trades of Gaurav Shah.

RCKT

163,310 shares

RCKT

Feb 11, 2025

Received

RCKT

$289.56K

RCKT at $13.05/share

Nov 21, 2024

Sale

RCKT

$178.56K

RCKT at $18.50/share

Aug 16, 2024

Sale

RCKT

$228.60K

RCKT at $23.35/share

May 14, 2024

Sale

RCKT

66,577 shares

RCKT

Feb 16, 2024

Received

RCKT

$604.88K

RCKT at $29.84/share

Feb 16, 2024

Sale

RCKT

$73.75K

RCKT at $15.47/share

Aug 17, 2023

Sale

RCKT

$88.11K

RCKT at $21.38/share

May 17, 2023

Sale

RCKT

$232.42K

RCKT at $19.06/share

Feb 17, 2023

Sale

RCKT

$381.51K

RCKT at $17.34/share

Feb 7, 2022

Purchase

Compensation History

See how much did Gaurav Shah make over time.

In 2023, Gaurav Shah's total compensation reached approximately $8 million, primarily through stock options rather than cash bonuses. His salary was around $625,000, which shows a steady income reflecting his position. The lack of a cash bonus this year indicates a shift in how Rocket wants to compensate its leaders, focusing on long-term gains from stock options. He received significant stock grants worth about $2.3 million, alongside stock options valued at around $4.6 million. This structure of compensation emphasizes performance tied directly to Rocket’s success, giving Shah and the company a shared goal. The total compensation package is designed to motivate leadership to meet corporate objectives and guarantee the growth of shareholder value. His previous year’s compensation was considerably lower, reflecting the company’s shift towards long-term growth strategies.

Year

2023

Total Compensation

$638.57K

Salary

$625.00K

Board Justification

The compensation program is designed to attract, motivate, and retain executive talent while aligning compensation with company performance and shareholder value.

Bonus

$0.00

Board Justification

No bonus was awarded for fiscal 2023.

Other

$13.57K

Board Justification

Other compensation includes company matching contributions to the 401(k) plan and life insurance costs.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus was on stock options and RSUs that are yet to vest.

Performance Metrics

Performance metrics for fiscal 2023 included achieving corporate objectives related to clinical development and maintaining a strong reputation.